DA Davidson initiated coverage of Cellebrite with a Buy rating and $20 price target. The company's total addressable market is large, growing, and likely understated, the analyst tells investors in a research note. The stock also offers multiple drivers of continued wallet share gains and achievement of guided to organic annualized recurring revenue growth acceleration, the firm added.
